The group's principal activity is to discover and develop antiviral medicines. The group is a development stage company. The group currently focuses on product discovery and development activities on a number of ribonucleic acid (rna) virus diseases affecting children and adults, including viral respiratory infection (vri), respiratory syncytial virus (rsv) disease and hepatitis c. The group also develops antiviral medicines for the diseases caused by deoxyribonucleic acid (dna).
